Withanolide B

Modify Date: 2025-08-27 09:02:29

Withanolide B Structure
Withanolide B structure
Common Name Withanolide B
CAS Number 56973-41-2 Molecular Weight 454.59800
Density 1.206 Boiling Point N/A
Molecular Formula C28H38O5 Melting Point N/A
MSDS Chinese USA Flash Point N/A

 Use of Withanolide B


Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].

 Names

Name Lycium substance B
Synonym More Synonyms

 Withanolide B Biological Activity

Description Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
Related Catalog
In Vitro Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs[1]. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP)[1]. Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs[1]. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells[2]. Cell Viability Assay[1] Cell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2.
In Vivo Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model[1]. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect[1] Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone.
References

[1]. Kuang Z, et, al. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/β-catenin signaling pathways. Int Immunopharmacol. 2020 Nov;88:106960.

[2]. Dubey S, et, al. Improving the inhibition of β-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021 Mar 15;173:56-65.

[3]. Sivanandha G, et, al. Enhanced biosynthesis of withanolides by elicitation and precursor feeding in cell suspension culture of Withania somnifera (L.) Dunal in shake-flask culture and bioreactor. PLoS One. 2014 Aug 4;9(8):e104005.

 Chemical & Physical Properties

Density 1.206
Molecular Formula C28H38O5
Molecular Weight 454.59800
Exact Mass 454.27200
PSA 76.13000
LogP 4.38050
InChIKey ZTEVDTFJUUJBLP-MBMSZCMESA-N
SMILES CC1=C(C)C(=O)OC(C(C)C2CCC3C4C5OC5C5(O)CC=CC(=O)C5(C)C4CCC23C)C1

 Safety Information

Hazard Statements H413
RIDADR NONH for all modes of transport

 Synonyms

UNII-9YU877VU8K
Withanolide B
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.